Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Stereoselective Pharmacokinetics and Chiral Inversion of Ibuprofen in Adjuvant-induced Arthritic Rats

Hiroyuki Ikuta, Atsushi Kawase and Masahiro Iwaki
Drug Metabolism and Disposition March 2017, 45 (3) 316-324; DOI: https://doi.org/10.1124/dmd.116.073239
Hiroyuki Ikuta
Department of Pharmacy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Kawase
Department of Pharmacy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Iwaki
Department of Pharmacy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

2-Arylpropionic acid (2-APA) nonsteroidal anti-inflammatory drugs are commonly used in racemic mixtures (rac) for clinical use. 2-APA undergoes unidirectional chiral inversion of the in vivo inactive R-enantiomer to the active S-enantiomer. Inflammation causes the reduction of metabolic activities of drug-metabolizing enzymes such as cytochrome P450 (P450) and UDP-glucuronosyltransferase. However, it is unclear whether inflammation affects the stereoselective pharmacokinetics and chiral inversion of 2-APA such as ibuprofen (IB). We examined the effects of inflammation on the pharmacokinetics of R-IB and S-IB after intravenous administration of rac-IB, R-IB, and S-IB to adjuvant-induced arthritic (AA) rats, an animal model of inflammation. The plasma protein binding of rac-IB, glucuronidation activities for R-IB and S-IB, and P450 contents of liver microsomes in AA rats were determined. Total clearance (CLtot) of IB significantly increased in AA rats, although the glucuronidation activities for IB, and P450 contents of liver microsomes decreased in AA rats. We presumed that the increased CLtot of IB in AA rats was caused by the elevated plasma unbound fraction of IB due to decreased plasma albumin levels in AA rats. Notably, CLtot of R-IB but not S-IB significantly increased in AA rats after intravenous administration of rac-IB. These results suggested that AA could affect drug efficacies after stereoselective changes in the pharmacokinetics of R-IB and S-IB.

Introduction

The 2-arylpropionic acid (2-APA) nonsteroidal anti-inflammatory drugs, with the exception of naproxen, are commonly used in racemic mixtures (rac) for clinical use. The S-enantiomer of 2-APA confers therapeutic effects via prostaglandin synthesis inhibition and causes adverse effects such as gastrointestinal irritation (Brune et al., 1992). 2-APA undergoes unidirectional chiral inversion of the in vivo inactive R-enantiomer to the active S-enantiomer, which appears to be species and compound dependent (Caldwell et al., 1988; Baillie et al., 1989; Knihinicki et al., 1989; Chen et al., 1990; Müller et al., 1990; Ahn et al., 1991; Chen et al., 1991; Rudy et al., 1991). Stereoselective pharmacokinetic studies of 2-APA have been performed in rodents and humans (Abas and Meffin, 1987; Foster et al., 1988; Jamali et al., 1988; Pedrazzini et al., 1988; Jamali and Brocks, 1990; Brocks and Jamali, 1994; Davies, 1995; Castro et al., 2001).

The liver is susceptible to inflammation such as viral and drug-induced hepatitis and is the primary organ for metabolism of xenobiotics and endogenous substrates. We previously demonstrated alterations in expression and activity of drug-metabolizing enzymes and transporters in inflammation using mice with collagen-induced arthritis (Kawase et al., 2007) and rats with adjuvant-induced arthritis (AA) (Uno et al., 2007,2009). AA rats have been used as a model of rheumatoid arthritis for the development of anti-inflammatory medicines because they exhibit systemic inflammatory disease with changes to bone and cartilage similar to those observed in humans with rheumatoid arthritis (Williams, 1992). Increases in inflammatory markers such as lactate dehydrogenase, aspartate aminotransferase, alkaline phosphatase, and α1-acid glycoprotein were observed in the serum of AA rats (Kawase et al., 2013). Several reports have shown that the elimination of propranolol (Walker et al., 1986; Piquette-Miller and Jamali, 1995), acebutolol (Piquette-Miller and Jamali, 1992), and cyclosporine (Pollock et al., 1989) from blood is delayed in AA rats. The alterations in drug pharmacokinetics in AA rats are possibly attributed to changes in plasma binding to albumin and impaired metabolism by metabolic enzymes such as cytochrome P450 (P450) and UDP-glucuronosyltransferase (UGT). Most 2-APA drugs are highly bound to plasma albumin and are mainly eliminated by hepatic metabolism. Meunier and Verbeeck (1999a) reported the stereoselective glucuronidation of ketoprofen in AA rats. They showed that AA rats exhibit significant impairment in the in vivo glucuronidation of ketoprofen. Consequently, the disposition of drugs that undergo low hepatic extraction can be especially affected by pathophysiological changes in arthritis. We demonstrated that the total clearance (CLtot) of flurbiprofen enhanced owing to a remarkable decrease in protein binding despite impaired intrinsic hepatic clearance (CLint) (Nagao et al., 2003).

However, there is little information regarding the pharmacokinetics of chiral inversion of 2-APA in arthritis, despite 2-APA being widely administered to patients suffering from arthritis. Ibuprofen (IB) as a model compound of 2-APA undergoes unidirectional chiral inversion of the inactive R-enantiomer to the active S-enantiomer in rats (Kaiser et al., 1976). We previously demonstrated that the intrinsic chiral inversion rate constant of IB and the metabolic degradation rate constants decreased in AA rats compared with those of control rats in freshly isolated rat hepatocytes (Uno et al., 2008). This in vivo study was carried out to clarify the effects of AA inflammation on the stereoselective pharmacokinetics of R-IB and S-IB and chiral inversion of IB after intravenous administration to rats.

Materials and Methods

Ethical Approval of the Study Protocol.

The study protocol was approved by the Committee for the Care and Use of Laboratory Animals of the Faculty of Pharmacy of Kindai University (Osaka, Japan).

Compounds and Reagents.

Rac-IB was purchased from Wako Pure Chemicals (Osaka, Japan). R-IB and S-IB were purchased from Cayman Chemical Company (Ann Arbor, MI) and Tokyo Kasei (Tokyo, Japan), respectively. Naproxen and etodolac, internal standards for high-performance liquid chromatography (HPLC), were purchased from Sigma Aldrich (St. Louis, MO) and Nippon Shinyaku (Kyoto, Japan), respectively. Rabbit polyclonal anti-acyl-coenzyme A synthetase (ACS)1 antibody (Bioss Antibodies, Woburn, MA), rabbit polyclonal anti-2-aryl propionyl-coenzyme A epimerase (APCE) antibody (Cell Signaling Technology, Danvers, MA), and mouse monoclonal anti-β-actin (Acris Antibodies, Herford, Germany). All other chemicals and solvents were of the best purity commercially available or of HPLC grade.

Preparation of AA Rats.

Female Sprague-Dawley rats (7 weeks old) weighing 150–170 g were purchased from Japan SLC (Shizuoka, Japan). The animals were housed in a temperature-controlled room with free access to standard laboratory food and water. AA rats were prepared according to a previously reported procedure (Kawase et al., 2014). Briefly, 1 mg heat-killed Mycobacterium butyricum was subcutaneously injected into the right hind footpad and tail base of rats (Difco Laboratories, Detroit, MI) as an adjuvant suspended in Bayol F oil (10 mg/ml). Hind paw volumes were measured using a liquid plethysmometer. Animals that exhibited severe inflammation at local and systemic sites at 21 days (chronic phase) after injection of the adjuvant were studied.

Animal Experiments.

On the day before drug administration, a cannula (silicone tubing; 0.5 mm inside diameter [ID], 1.0 mm outside diameter [OD]) was implanted in the right jugular vein under pentobarbital anesthesia (40 mg/kg, intraperitoneally). On day 21 after AA induction, the bile ducts of the animals were cannulated with polyethylene tubing (PE-10; 0.28 mm ID, 0.61 mm OD) to avoid possible enterohepatic circulation of IB (Dietzel et al., 1990). Animals received intravenous administration of either rac-IB (20 mg/kg) or each IB enantiomer (10 mg/kg) through the jugular vein cannula, followed by 0.3 ml of sterile heparinized saline to flush the tubing. Blood samples were collected 1, 5, 10, 20, 30, 45, 60, 90, and 120 minutes after administration and were centrifuged for 10 minutes at 3000 g. Because of the instability of acyl glucuronides at physiologic pH, plasma was transferred to a tube containing 5 μl 17% phosphoric acid. The plasma was immediately frozen on dry ice and stored at –80°C until analysis.

Protein Binding Study.

In vitro filtrated unbound IB at a total concentration of 50 μg/ml was determined by ultrafiltration (MINICENT-10, Tosoh, Tokyo, Japan) of plasma samples from control and AA rats without IB treatment to evaluate the plasma protein binding of IB. In vivo plasma protein binding in control and AA rats was also measured after intravenous administration of rac-IB (20 mg/kg). Preliminary studies indicated that IB did not bind to the ultrafiltration device. Plasma albumin and total protein concentrations were determined by an automatic analytical device (Olympus AU5200, Olympus, Tokyo, Japan).

Glucuronidation Activities and P450 Contents in Liver Microsomes.

The UGT activities in rat liver microsomes for IB enantiomers were determined. After incubating 1 mM IB for 10 minutes in the microsomal suspension in 0.1 M Tris-HCl buffer (pH 7.4) including 1 mg/ml microsome, 10 mM MgCl2, 0.2% Triton X-100, 2 mM phenyl methyl sulfonyl fluoride, 20 mM 1,4-saccharolactone, and 10 mM UDP-glucuronic acid, the concentrations of IB glucuronide (IBG) formed were stereoselectively determined by HPLC. P450 contents in rat liver microsomes were determined by the method described by Omura and Sato (1964).

Sample Preparation for HPLC Analysis.

Naproxen (50 μl) in methanol (1 μg/ml) was added as an internal standard to mixtures of 100 μl plasma and 400 μl acetic acid (pH 2.5). After the addition of 2 ml ethyl acetate, the mixture was shaken for 10 minutes and centrifuged at 2000 g for 5 minutes. The organic layer was transferred to another clean tube and evaporated to dryness using a centrifugal evaporator (Tokyo Rikakikai, Tokyo, Japan) at 35°C. The 20-μl residue dissolved in 100 μl of mobile phase was injected into the HPLC system. For bile samples, 50 μl of etodolac in methanol (5 μg/ml) as an internal standard and 100 μl of methanol were added to bile diluted 10 times with purified water. The mixture was vortexed for 30 seconds and centrifuged at 2000 g for 5 minutes, and the 20 μl supernatant was directly injected into the HPLC system.

HPLC Conditions.

HPLC analysis was performed using a conventional ODS column (Cosmosil 5C18-AR-II, 4.6 × 250 mm, 5 μm, Nacalai Tesque, Kyoto, Japan) for rac-IB and a chiral column (Chiral OJ-R, 4.6 × 150 mm, 5 μm, Daicel Chemical, Tokyo, Japan) for R-IB, S-IB, R-IBG, and S-IBG using a Shimadzu HPLC system equipped with an ultraviolet detector (220 nm for IB assay; 232 nm for IBG assay). The mobile phases [0.2 M phosphate buffer, pH 2.0/acetonitrile (67.5:32.5, v/v) for IB assay, and 0.05 M phosphate buffer including 2 mM tetra-n-butylammonium hydrogen sulfate, pH 5.5/acetonitrile (65:35, v/v) for IBG] were pumped at a flow rate of 1 ml/min.

Pharmacokinetic Analysis.

Plasma concentration data for IB were fitted to the mass balance equation for a conventional two-compartment open model with unidirectional inversion from R-IB to S-IB (Fig. 1) (Knihinicki et al., 1990). We tried to one- and two-compartment model including chiral inversion. The Akaike’s information criterion of two-compartment model was smaller than that of one-compartment model. Pharmacokinetic parameters were obtained by the nonlinear least square method using WinNonlin software (Pharsight, Mountain View, CA). Plasma concentration-time profiles of S-IB after intravenous administration of S-IB were fitted to the following equations:Embedded Image(1)Embedded Image(2)where C1(S) is the plasma concentration of S-IB in the central compartment; X1(S) and X2(S) are the amounts of S-IB in the central and peripheral compartments, respectively; V1(S) is the volume of distribution of the central compartment; k10(S), k12(S), and k21(S) are the first-order rate constants as shown in Fig. 1.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

A pharmacokinetic model with unidirectional inversion from R-IB to S-IB.

Plasma concentration-time profiles of R-IB and S-IB after intravenous administration of R-IB were fitted to the following equations:Embedded Image(3)Embedded Image(4)Embedded Image(5)Embedded Image(6)where C1(R) is the plasma concentration of R-IB in the central compartment; V1(R) is the volume of distribution of the central compartment; k10(R) = k0(R) + kRS, and k0(R), kRS, k12(R), and k21(R) are the first-order rate constants as shown in Fig. 1. For the fitting of plasma concentration-time profiles of S-IB after intravenous administration of R-IB, parameter values obtained for S-IB after intravenous administration of S-IB were used for V1(S), k10(S), k12(S), and k21(S). Therefore, V1(R), k10(R), k0(R), kRS, k12(R), and k21(R) were estimated from the fitting.

CLtot, chiral inversion clearance (CLRS), and metabolic clearance (CLMET) were calculated using the following equations:

Embedded Image(7)Embedded Image(8)Embedded Image(9)

The fraction inverted from R-IB to S-IB after R-IB administration (Fi) was calculated using three approaches: the area under the plasma concentration-time curve (AUC) comparison, the deconvolution, and pharmacokinetic modeling methods. The fractional inversion using AUC (FiAUC) was calculated using the principles discussed by Pang and Kwan (1983) with the following equation:Embedded Image(10)where AUCR→S is the AUC0-∞ of the metabolically formed S-IB after R-IB administration and AUCS→S is the AUC0-∞ of S-IB after S-IB administration, assuming equal doses of R-IB and S-IB and no inversion from the S-IB to the R-IB (Adams et al., 1976; Hutt and Caldwell, 1983).

Determination of Protein Levels by Western Blot.

Hepatic microsomes of control and AA rats were prepared according to a previously reported procedure (Iwaki et al., 1995; Nozaki et al., 2007). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed using 7.5% e-Pagell (Atto, Tokyo, Japan) and 50 μg microsome per well. Resolved proteins were transferred onto Hybond-P polyvinylidene difluoride membranes (GE Healthcare, Milwaukee, WI). Immunoreactive ACS1, APCE, and β-actin were detected using antibodies and an ECL Prime Western Blotting Detection system (GE Healthcare).

Statistical Analysis.

The significant difference of the mean values between groups was estimated using analysis of variance followed by the Bonferroni test. A P value of <0.05 was considered statistically significant.

Results

The plasma concentration-time profiles of IB enantiomers after intravenous bolus injection of rac-IB (20 mg/kg) to control and AA rats were determined (Fig. 2). The plasma R-IB in both control and AA rats was rapidly eliminated. The plasma concentrations of both enantiomers in AA rats were slightly lower than corresponding antipodes in the controls. The noncompartmental pharmacokinetic parameters estimated from the results in Fig. 2 are summarized in Table 1. The stereoselective pharmacokinetics of IB were observed; for R-IB, relatively higher total clearance (CLtot) and shorter mean residence time were observed compared with those of S-IB in both control and AA rats. There were no significant differences in distribution volumes at steady state (Vdss) between enantiomers, although the volumes of R-IB tended to be large. The CLtot of each enantiomer was approximately 1.5 times increased in AA rats compared with that of control rats, although the increase in CLtot of S-IB in AA rats was not significant.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Plasma concentration-time profiles of IB enantiomers after intravenous administration of rac-IB (20 mg/kg) in control and AA rats.△, R-IB; ○, S-IB in control rat; ▴, R-IB; ●, S-IB in AA rats. Solid lines represent the fitting curves using the pharmacokinetic model shown in Fig. 1. Results are expressed as the mean ± S.D. (n = 3).

View this table:
  • View inline
  • View popup
TABLE 1

Noncompartmental pharmacokinetic parameters of each enantiomer after intravenous administration of rac-IB

Results are expressed as the mean ± SD (n = 3).

To elucidate the effect of AA on the chiral inversion of R-IB to the S-antipode, compartment model analysis including the inversion process was performed. The pharmacokinetic parameters obtained from the model for each enantiomer of IB are summarized in Table 2. The distribution volume of the central compartment (V1) and the peripheral compartment (V2) of R-IB and S-IB in AA rats were slightly higher compared with those of the controls. There were no significant differences in metabolic clearance (CLMET) between enantiomers in either control or AA rats. However, the CLtot of R-IB was significantly higher than that of S-IB owing to the inversion of R-IB to S-IB. The inversion clearance (CLRS) and CLMET of R-IB increased in AA rats; the CLtot, CLRS, and CLMET values were approximately 1.5 times higher in AA rats. On the other hand, there were no significant differences in CLtot and CLMET of S-IB between control and AA rats. Slight differences in k0(R), k12, k21, k10, and kRS were observed between control and AA rats. The inversion rate constants (kRS) for R-IB in control and AA rats were 0.044 and 0.052 minute−1, respectively, which accounted for approximately 70% of k10.

View this table:
  • View inline
  • View popup
TABLE 2

Compartmental pharmacokinetic parameters of each enantiomer after intravenous administration of rac-IB

Results are expressed as the mean ± S.D. (n = 3).

To further clarify the effects of AA on the pharmacokinetics of each enantiomer, plasma concentration profiles of the IB enantiomers after the intravenous administration of either R-IB or S-IB were examined (Fig. 3). R-IB was not detected in plasma after S-IB administration, indicating that no or negligible inversion from S-IB to R-IB occurred in rats. S-IB was observed in plasma after R-IB administration, demonstrating the in vivo inversion of R-IB to S-IB. Plasma concentrations of S-IB increased up to approximately 20 minutes after the administration of R-IB. Subsequently, both R-IB and S-IB concentrations decreased and the concentrations of S-IB were higher than those of R-IB from approximately 30 minutes onward. The noncompartmental and compartmental pharmacokinetic parameters of R-IB and S-IB after intravenous administration of each enantiomer were estimated (Tables 3 and 4). The T1/2 and Vdss for R-IB and S-IB did not change between control and AA rats. The CLtot of R-IB and S-IB in AA rats significantly increased compared with those in control rats. The AUCs of each enantiomer after administration of the respective enantiomer and of S-IB after R-IB administration in AA rats significantly decreased compared with those in control rats. Table 4 demonstrates the tendency for V1 and V2 to be increased in AA rats after rac-IB administration. The CLtot and CLMET of R-IB and S-IB in AA rats significantly increased compared with those in control rats, the results being similar to those after intravenous administration of rac-IB. The fraction inverted from R-IB to S-IB after R-IB administration (Fi) and the half-life for inversion (T1/2inv) in control and AA rats were estimated using AUC analysis, deconvolution method, and model analysis (Table 5). The Fi values of R-IB in both control and AA rats were approximately 50%, indicating that half of R-IB underwent chiral inversion to S-IB and that little difference in Fi values was observed between control and AA rats.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Plasma concentration-time profiles of IB enantiomers after intravenous administration of S-IB (10 mg/kg) (A) or R-IB (10 mg/kg) (B) in control and AA rats. △, R-IB; ○, S-IB in control rat; ▴, R-IB; ●, S-IB in AA rats. Solid lines represent the fitting curves using the pharmacokinetic model shown in Fig. 1. Results are expressed as the mean ± S.D. (n = 3).

View this table:
  • View inline
  • View popup
TABLE 3

Noncompartmental pharmacokinetic parameters of each enantiomer after intravenous administration of R-IB or S-IB

Results are expressed as the mean ± S.D. (n = 3).

View this table:
  • View inline
  • View popup
TABLE 4

Compartmental pharmacokinetic parameters of each enantiomer after intravenous administration of R-IB or S-IB

Results are expressed as the mean ± S.D. (n = 3).

View this table:
  • View inline
  • View popup
TABLE 5

Fi and T1/2inv of inversion calculated by AUC analysis, deconvolution method, and model analysis in control and AA rats

Results are expressed as the mean ± S.D. (n = 3).

The protein levels of ACS1 and APCE in hepatic microsomes of control and AA rats were determined (Fig. 4). ACS1 and APCE are involved in chiral inversion of IB. The protein levels of ACS1 were unchanged between control and AA rats. The significant decreases of APCE expression in AA rats were observed.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Relative protein levels of ACS1 and APCE in hepatic microsomes of control and AA rats. Results are expressed as the mean ± S.D. (n = 5 or 6). Significant differences between control and AA rats are indicated. ***P < 0.001.

Metabolic enzyme activities and plasma protein binding are the most important determinants of the pharmacokinetics of 2-APA. To clarify whether AA affected metabolic enzyme activities, we measured the glucuronidation activities and P450 contents of rat liver microsomes (Table 6). The glucuronidation activities for S-IB were approximately three to four times higher than those for R-IB in control and AA rats. AA induction resulted in a significant decrease in glucuronidation activities and P450 contents for both R-IB and S-IB, suggesting that phase І and ІІ metabolisms for IB were reduced in AA rats. Total protein and albumin concentrations and the plasma protein binding of R-IB and S-IB in control and AA rats were measured (Tables 7 and 8). Serum total protein and albumin concentrations in AA rats significantly decreased compared with those in control rats. In particular, the decreases in albumin concentrations in AA rats were marked (approximately 65% of control). Both in vitro and in vivo plasma unbound fractions (fu) of both enantiomers of IB in AA rats increased approximately 2.5 times compared with those in controls, although fu of S-IB was significantly greater than those of R-IB in both control and AA rats.

View this table:
  • View inline
  • View popup
TABLE 6

Glucuronidation activities for R-IB and S-IB and P450 contents in control and AA rats

Results are expressed as the mean ± S.D. (n = 3).

View this table:
  • View inline
  • View popup
TABLE 7

Plasma levels of total protein and albumin in control and AA rats

Results are expressed as the mean ± S.D. (n = 3).

View this table:
  • View inline
  • View popup
TABLE 8

In vitro and in vivo plasma unbound fractions (fu) (%) of IB in control and AA rats

Results are expressed as the mean ± S.D. (n = 3).

Discussion

In arthritis, P450 activities and plasma protein levels are decreased (Toda et al., 1994; Meunier and Verbeeck, 1999a; Kawase et al., 2013). In AA rats, used as a model of rheumatic arthritis, the pharmacokinetics of various drugs are affected, owing to the alterations in P450 activities and plasma protein levels (Walker et al., 1986; Pollock et al., 1989; Piquette-Miller and Jamali, 1992,1995; Meunier and Verbeeck, 1999b). For example, the CLtot of the unbound form of ketoprofen significantly decreased in AA rats, whereas that of total (bound and unbound) ketoprofen was unchanged (Meunier and Verbeeck, 1999b). We also reported that CLtot of flurbiprofen increased approximately twofold in AA rats (Nagao et al., 2003). In the present study, we examined the effects of AA on the stereoselective pharmacokinetics, especially on chiral inversion, of IB in rats.

In AA rats, CLtot of IB significantly increased, although the glucuronidation activities for IB and P450 contents in liver microsomes decreased to approximately 50% and 70%, respectively; it is unclear whether AA affects the protein or activity of UGT and P450 isoforms. Probably, the increased CLtot of IB was caused by the elevated levels of fu of IB due to the decreased plasma albumin levels in AA rats (Tables 7 and 8). We previously demonstrated that the changed plasma protein levels in AA rats leading to altered protein binding of drugs affect the pharmacokinetics of propranolol and flurbiprofen, which extensively bind to plasma protein under inflammatory conditions (Kawase et al., 2013). In humans, IB is also extensively (>98%) bound to albumin at therapeutic concentrations (Davies, 1998) and fu of S-IB is twofold higher compared with that of R-IB, similar to the results in Table 8 (Evans et al., 1990; Tan et al., 2002). It is important to clarify the effects of AA on plasma levels of S-IB, because S-IB is involved in the expression of drug actions. In AA rats, decreased plasma levels of S-IB were observed after intravenous injection of rac-IB, R-IB, or S-IB compared with control rats (Figs. 2 and 3) without change of Fi and T1/2inv, suggesting that drug actions of IB may be reduced in AA rats.

It is known that nonsteroidal anti-inflammatory drugs such as IB are conjugated in the liver to acyl glucuronides and excreted in bile (Mills et al., 1973). The efficiency of glucuronidation for R-IB or S-IB was suppressed in AA rats to 51% or 44% of control rats, respectively (Table 6). These results agreed with the report about ketoprofen by Meunier et al. (Meunier and Verbeeck, 1999b). The P450 contents in liver microsomes of AA rats significantly decreased by approximately 70% compared with that of control rats. Because most 2-APA including IB have relatively low levels of hepatic extraction, CLtot of these drugs depends on both fu and CLint. IB is mainly metabolized by P450 and UGT (Hamman et al., 1997; Buchheit et al., 2011). The CLint of AA rats could be decreased to approximately half the value of control rats because CLint reflects the ability to eliminate the metabolized drug from the liver. Therefore, the increase of approximately 1.5 times in CLMET of IB in AA rats after rac-IB administration could be a response to changes in fu and CLint, that is, in vivo plasma fu of IB approximately 2.5 times (Table 8) and CLint decreased by approximately half compared with that in control rats. Meunier and Verbeeck (1999b) showed that CLtot of ketoprofen in AA rats did not significantly change. This result was interpreted as the approximately doubled fu levels of ketoprofen negated the effect of decreased CLint levels. The markedly elevated CLtot of flurbiprofen in AA rats was assumed to be induced by the relatively higher protein-binding ratio of nonsteroidal anti-inflammatory drugs (Borgå and Borgå, 1997; Nagao et al., 2003). After intravenous administration of R-IB or S-IB, the effects of AA on CLtot, CLRS, and CLMET of S-IB were larger compared with those of R-IB, although rac-IB exhibited similar effects of AA on CLtot and CLMET between R-IB and S-IB (Fig. 5). As these results demonstrate, there were some differences between the pharmacokinetics of each enantiomer of IB after intravenous administration of rac-IB and those after intravenous administration of R-IB or S-IB. Itoh et al. (1997) demonstrated that the enantiomer-enantiomer interaction in plasma protein binding affected the stereoselective pharmacokinetics of IB. Therefore, with intravenous administration of rac-IB, it is necessary to consider the interactions between R-IB and S-IB in addition to the pharmacokinetics of each enantiomer.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Effects of AA induction on CLRS (ml/min/kg) and CLMET (ml/min/kg) of IB. Chiral centers indicated by an asterisk.

The plasma concentrations of S-IB were significantly higher compared with those of R-IB after intravenous administration of rac-IB (Fig. 2). Similar stereoselective pharmacokinetics was observed for ketoprofen or fenoprofen (Rubin et al., 1985; Jamali and Brocks, 1990), suggesting that the higher CLtot of R-IB compared with that of S-IB could be due to the process of chiral inversion in CLtot of R-IB. Similar values for CLMET between R-IB and S-IB were observed in control and AA rats (Table 2). The CLtot of S-IB or R-IB could be expressed by the following equations:Embedded Image(11)Embedded Image(12)CLox and CLglu indicate the metabolic clearance of unbound IB for hydroxylation and glucuronidation, respectively. The following equation was derived from eq. 12.

Embedded Image(13)

It is possible that the hydroxylation activity for S-IB was dominant compared with that of R-IB because similar values of CLMET were exhibited despite the higher fu and CLglu of S-IB (Tables 6 and 8). Hamman et al. (1997) and Chang et al. (2008) showed the similar extents of stereoselective metabolisms of IB enantiomers by CYP2C. In in vivo study, P450-mediated clearance is more important for the S-IB (∼70%) compared with the R-IB (∼30%), because the unidirectional chiral inversion of R-IB to S-IB occurs (Rudy et al., 1991; Davies 1998). Glucuronidation activity for S-IB was 3 to 4 times higher than R-IB (Table 6), although the detailed mechanisms of preferential glucuronidation of S-IB is unclear. Our results concur with the report of el Mouelhi et al. (1987) that S-IB tends to convert to glucuronide compared with R-IB.

R-IB was undetectable in plasma after intravenous administration of S-IB (Fig. 3A), whereas S-IB was observed in plasma after intravenous administration of R-IB (Fig. 3B). These results were consistent with those of the studies by Knihinicki et al. (1991), Itoh et al. (1997), and Chen et al. (1991) on the unidirectional chiral inversion in rat. The Fi of IB in control was about 50%, indicating that a half of R-IB underwent chiral inversion to S-IB. This result agreed with those of the studies by Knihinicki et al. (1991), Itoh et al. (1997), and Lee et al. (1984). Interestingly, little difference was observed between the Fi and T1/2inv values of control and those of AA (Table 5). Chiral inversion comprises the following four steps (Knihinicki et al., 1989; Menzel et al., 1994): 1) the formation of R-ibuprofenyl-adenylate from R-IB, 2) the activation process from R-ibuprofenyl-adenylate to R-IB-CoA thioester by long-chain fatty acid ACS, 3) the racemization process of R-IB-CoA thioester by 2-aryl propionyl-CoA epimerase, and 4) the process of release of free IB by hydrolysis enzyme. APCE is present mainly in the liver and kidney (Shieh and Chen, 1993; Reichel et al., 1997). In inflammatory conditions, the activities of metabolic enzymes in the liver reduced as shown in this study (Table 6) and by other groups (Toda et al., 1994; Meunier and Verbeeck 1999a). However, in vivo efficiencies of chiral inversion of IB were not affected by AA. The protein levels of APCE1 but not ACS1 in AA rats significantly decreased compared with control rats (Fig. 4). These results suggested that the efficiencies of epimerization but not the formation of CoA thioester in chiral inversion from R-IB to S-IB could decrease in AA rats, if the protein binding (free fraction) is unchanged in AA rats. However, the decreased protein levels of APCE in AA rats have little effect on the chiral inversion ratio of IB, because the rate-limiting step in the chiral inversion of IB is CoA thioester formation but not epimerization and ibuprofenyl-CoA formation (Knihinicki et al., 1989; Knadler and Hall, 1990; Knights et al., 1991; Tracy and Hall, 1992). Few reports are available on the chiral inversion of S-IB to R-IB. The CLtot, CLRS, and CLMET depend on both the metabolic activities and the protein binding of IB. The plasma unbound fraction of IB in AA rats was 2 to 3 times higher than that in control rats (Table 8). The glucuronidation activity and P450 contents in AA rats significantly decreased (Table 6). The P450 activities in AA rats also decreased, e.g., Cyp3a activities in AA rats reduced to approximately 20% of control (data not shown). As a cause of disagreements between the changes of CL and chiral inversion ratio in AA rats, there is a possibility that the decreased activities of P450, UGT, and enzymes catalyzing chiral inversion in AA rats are counterbalanced by the increased plasma free fraction of IB. Consequently, the ratios of chiral inversion were unchanged between control and AA rats. The effects of alterations in protein binding for IB on IB pharmacokinetics could possibly be larger than those in APCE activities in AA rats. Consequently, the ratios of chiral inversion could be unchanged between control and AA rats.

AA rats exhibit systemic inflammatory disease with changes to bone and cartilage similar to those observed in humans with rheumatoid arthritis (Williams, 1992). The effects of inflammation in arthritic patients on stereoselective pharmacokinetics is very interesting. However, it is unclear whether the human arthritis affects the stereoselective pharmacokinetics of 2-aryl propionic NSAIDs such as IB. A further study of changes of chiral inversion in arthritic patients should be conducted.

In conclusion, remarkable effects of AA on CLtot of S-IB were observed compared with that of R-IB without changes in chiral inversion ratios from R-IB to S-IB after intravenous administration of R-IB or S-IB, although there were slight alterations in the effects of AA on CLtot between stereoisomers after intravenous administration of rac-IB. These changes in the stereoselective pharmacokinetics of IB via decreased activity of P450 and UGT and elevated fu could affect drug efficiencies.

Authorship Contributions

Participated in research design: Iwaki.

Conducted experiments: Ikuta and Kawase.

Performed data analysis: Ikuta and Kawase.

Wrote or contributed to the writing of the manuscript: Kawase and Iwaki.

Footnotes

    • Received August 23, 2016.
    • Accepted December 1, 2016.
  • This work was supported by the “Antiaging” Project for Private Universities, with a matching fund subsidy from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); the MEXT-Supported Program for the Strategic Research Foundation at Private Universities 2014-2018 [Grant S1411037].

  • dx.doi.org/10.1124/dmd.116.073239.

Abbreviations

2-APA
2-arylpropionic acid
AA
adjuvant-induced arthritis
ACS
acyl-coenzyme A synthetase
APCE
2-aryl propionyl-coenzyme A epimerase
AUC
area under the plasma concentration-time curve
CLint
intrinsic hepatic clearance
CLMET
metabolic clearance
CLRS
chiral inversion clearance
CLtot
total clearance
fu
unbound fractions
HPLC
high-performance liquid chromatography
IB
ibuprofen
IBG
ibuprofen glucuronide
ID
inside diameter
kRS
inversion rate constants
OD
outside diameter
P450
cytochrome P450
rac
racemic mixtures
T1/2inv
half-life for inversion
UGT
UDP-glucuronosyltransferase
V1
central compartment
V2
peripheral compartment
Vdss
distribution volumes at steady state
  • Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Abas A and
    2. Meffin PJ
    (1987) Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. IV. Ketoprofen disposition. J Pharmacol Exp Ther 240:637–641.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Adams SS,
    2. Bresloff P, and
    3. Mason CG
    (1976) Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J Pharm Pharmacol 28:256–257.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ahn HY,
    2. Amidon GL, and
    3. Smith DE
    (1991) Stereoselective systemic disposition of ibuprofen enantiomers in the dog. Pharm Res 8:1186–1190.
    OpenUrlPubMed
  4. ↵
    1. Baillie TA,
    2. Adams WJ,
    3. Kaiser DG,
    4. Olanoff LS,
    5. Halstead GW,
    6. Harpootlian H, and
    7. Van Giessen GJ
    (1989) Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharmacol Exp Ther 249:517–523.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Borgå O and
    2. Borgå B
    (1997) Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm 25:63–77.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Brocks DR and
    2. Jamali F
    (1994) Etodolac clinical pharmacokinetics. Clin Pharmacokinet 26:259–274.
    OpenUrlPubMed
  7. ↵
    1. Brune K,
    2. Geisslinger G, and
    3. Menzel-Soglowek S
    (1992) Pure enantiomers of 2-arylpropionic acids: tools in pain research and improved drugs in rheumatology. J Clin Pharmacol 32:944–952.
    OpenUrlPubMed
  8. ↵
    1. Buchheit D,
    2. Dragan CA,
    3. Schmitt EI, and
    4. Bureik M
    (2011) Production of ibuprofen acyl glucosides by human UGT2B7. Drug Metab Dispos 39:2174–2181.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Caldwell J,
    2. Hutt AJ, and
    3. Fournel-Gigleux S
    (1988) The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 37:105–114.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Castro EF,
    2. Soraci AL,
    3. Franci R,
    4. Fogel FA, and
    5. Tapia MO
    (2001) Disposition of suprofen enantiomers in the cat. Vet J 162:38–43.
    OpenUrlPubMed
  11. ↵
    1. Chang SY,
    2. Li W,
    3. Traeger SC,
    4. Wang B,
    5. Cui D,
    6. Zhang H,
    7. Wen B, and
    8. Rodrigues AD
    (2008) Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 36:2513–2522.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Chen CS,
    2. Chen T, and
    3. Shieh WR
    (1990) Metabolic stereoisomeric inversion of 2-arylpropionic acids. On the mechanism of ibuprofen epimerization in rats. Biochim Biophys Acta 1033:1–6.
    OpenUrlPubMed
  13. ↵
    1. Chen CS,
    2. Shieh WR,
    3. Lu PH,
    4. Harriman S, and
    5. Chen CY
    (1991) Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochim Biophys Acta 1078:411–417.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Davies NM
    (1995) Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 28:100–114.
    OpenUrlPubMed
  15. ↵
    1. Davies NM
    (1998) Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 34:101–154.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Dietzel K,
    2. Beck WS,
    3. Schneider HT,
    4. Geisslinger G, and
    5. Brune K
    (1990) The biliary elimination and enterohepatic circulation of ibuprofen in rats. Pharm Res 7:87–90.
    OpenUrlCrossRefPubMed
  17. ↵
    1. el Mouelhi M,
    2. Ruelius HW,
    3. Fenselau C, and
    4. Dulik DM
    (1987) Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids. Naproxen, ibuprofen, and benoxaprofen. Drug Metab Dispos 15:767–772.
    OpenUrlAbstract
  18. ↵
    1. Evans AM,
    2. Nation RL,
    3. Sansom LN,
    4. Bochner F, and
    5. Somogyi AA
    (1990) The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharm Drug Dispos 11:507–518.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Foster RT,
    2. Jamali F,
    3. Russell AS, and
    4. Alballa SR
    (1988) Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. J Pharm Sci 77:70–73.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hamman MA,
    2. Thompson GA, and
    3. Hall SD
    (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54:33–41.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hutt AJ and
    2. Caldwell J
    (1983) The metabolic chiral inversion of 2-arylpropionic acids--a novel route with pharmacological consequences. J Pharm Pharmacol 35:693–704.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Itoh T,
    2. Maruyama J,
    3. Tsuda Y, and
    4. Yamada H
    (1997) Stereoselective pharmacokinetics of ibuprofen in rats: effect of enantiomer-enantiomer interaction in plasma protein binding. Chirality 9:354–361.
    OpenUrl
  23. ↵
    1. Iwaki M,
    2. Bischer A,
    3. Nguyen AC,
    4. McDonagh AF, and
    5. Benet LZ
    (1995) Stereoselective disposition of naproxen glucuronide in the rat. Drug Metab Dispos 23:1099–1103.
    OpenUrlAbstract
  24. ↵
    1. Jamali F,
    2. Berry BW,
    3. Tehrani MR, and
    4. Russell AS
    (1988) Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J Pharm Sci 77:666–669.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Jamali F and
    2. Brocks DR
    (1990) Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 19:197–217.
    OpenUrlPubMed
  26. ↵
    1. Kaiser DG,
    2. Vangiessen GJ,
    3. Reischer RJ, and
    4. Wechter WJ
    (1976) Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci 65:269–273.
    OpenUrlPubMed
  27. ↵
    1. Kawase A,
    2. Tsunokuni Y, and
    3. Iwaki M
    (2007) Effects of alterations in CAR on bilirubin detoxification in mouse collagen-induced arthritis. Drug Metab Dispos 35:256–261.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Kawase A,
    2. Ikuta H,
    3. Uno S,
    4. Yamamoto K,
    5. Akitsu N,
    6. Nagao T, and
    7. Iwaki M
    (2013) Alteration in plasma protein binding properties of propranolol and flurbiprofen during development of adjuvant-induced arthritis in rats. Xenobiotica 43:246–252.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Kawase A,
    2. Norikane S,
    3. Okada A,
    4. Adachi M,
    5. Kato Y, and
    6. Iwaki M
    (2014) Distinct alterations in ATP-binding cassette transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats. J Pharm Sci 103:2556–2564.
    OpenUrl
  30. ↵
    1. Knadler MP and
    2. Hall SD
    (1990) Stereoselective arylpropionyl-CoA thioester formation in vitro. Chirality 2:67–73.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Knights KM,
    2. Addinall TF, and
    3. Roberts BJ
    (1991) Enhanced chiral inversion of R-ibuprofen in liver from rats treated with clofibric acid. Biochem Pharmacol 41:1775–1777.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Knihinicki RD,
    2. Williams KM, and
    3. Day RO
    (1989) Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs--1. In vitro studies of ibuprofen and flurbiprofen. Biochem Pharmacol 38:4389–4395.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Knihinicki RD,
    2. Day RO,
    3. Graham GG, and
    4. Williams KM
    (1990) Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality 2:134–140.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Knihinicki RD,
    2. Day RO, and
    3. Williams KM
    (1991) Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs--II. Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters. Biochem Pharmacol 42:1905–1911.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Lee EJ,
    2. Williams KM,
    3. Graham GG,
    4. Day RO, and
    5. Champion GD
    (1984) Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans. J Pharm Sci 73:1542–1544.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Menzel S,
    2. Waibel R,
    3. Brune K, and
    4. Geisslinger G
    (1994) Is the formation of R-ibuprofenyl-adenylate the first stereoselective step of chiral inversion? Biochem Pharmacol 48:1056–1058.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Meunier CJ and
    2. Verbeeck RK
    (1999a) Glucuronidation of R- and S-ketoprofen, acetaminophen, and diflunisal by liver microsomes of adjuvant-induced arthritic rats. Drug Metab Dispos 27:26–31.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Meunier CJ and
    2. Verbeeck RK
    (1999b) Glucuronidation kinetics of R,S-ketoprofen in adjuvant-induced arthritic rats. Pharm Res 16:1081–1086.
    OpenUrlPubMed
  39. ↵
    1. Mills RF,
    2. Adams SS,
    3. Cliffe EE,
    4. Dickinson W, and
    5. Nicholson JS
    (1973) The metabolism of ibuprofen. Xenobiotica 3:589–598.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Müller S,
    2. Mayer JM,
    3. Etter JC, and
    4. Testa B
    (1990) Metabolic chiral inversion of ibuprofen in isolated rat hepatocytes. Chirality 2:74–78.
    OpenUrl
  41. ↵
    1. Nagao T,
    2. Tanino T, and
    3. Iwaki M
    (2003) Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats. Chirality 15:423–428.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Nozaki Y,
    2. Kusuhara H,
    3. Kondo T,
    4. Iwaki M,
    5. Shiroyanagi Y,
    6. Nakayama H,
    7. Horita S,
    8. Nakazawa H,
    9. Okano T, and
    10. Sugiyama Y
    (2007) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322:1162–1170.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Omura T and
    2. Sato R
    (1964) Carbon monoxide-binding pigment of liver microsomes. I: Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378.
    OpenUrlFREE Full Text
  44. ↵
    1. Pang KS and
    2. Kwan KC
    (1983) A commentary: methods and assumptions in the kinetic estimation of metabolite formation. Drug Metab Dispos 11:79–84.
    OpenUrlPubMed
  45. ↵
    1. Pedrazzini S,
    2. De Angelis M,
    3. Muciaccia WZ,
    4. Sacchi C, and
    5. Forgione A
    (1988) Stereochemical pharmacokinetics of the 2-arylpropionic acid non-steroidal antiinflammatory drug flunoxaprofen in rats and in man. Arzneimittelforschung 38:1170–1175.
    OpenUrlPubMed
  46. ↵
    1. Piquette-Miller M and
    2. Jamali F
    (1992) Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agents Actions 37:290–296.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Piquette-Miller M and
    2. Jamali F
    (1995) Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos 23:240–245.
    OpenUrlAbstract
  48. ↵
    1. Pollock SH,
    2. Matthews HW, and
    3. D’Souza MJ
    (1989) Pharmacokinetic analysis of cyclosporine in adjuvant arthritic rats. Drug Metab Dispos 17:595–599.
    OpenUrlAbstract
  49. ↵
    1. Reichel C,
    2. Brugger R,
    3. Bang H,
    4. Geisslinger G, and
    5. Brune K
    (1997) Molecular cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen. Mol Pharmacol 51:576–582.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Rubin A,
    2. Knadler MP,
    3. Ho PPK,
    4. Bechtol LD, and
    5. Wolen RL
    (1985) Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans. J Pharm Sci 74:82–84.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Rudy AC,
    2. Knight PM,
    3. Brater DC, and
    4. Hall SD
    (1991) Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. J Pharmacol Exp Ther 259:1133–1139.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Shieh WR and
    2. Chen CS
    (1993) Purification and characterization of novel “2-arylpropionyl-CoA epimerases” from rat liver cytosol and mitochondria. J Biol Chem 268:3487–3493.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Tan SC,
    2. Patel BK,
    3. Jackson SH,
    4. Swift CG, and
    5. Hutt AJ
    (2002) Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers. Xenobiotica 32:683–697.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Toda A,
    2. Ishii N,
    3. Kihara T,
    4. Nagamatsu A, and
    5. Shimeno H
    (1994) Effect of adjuvant-induced arthritis on hepatic drug metabolism in rats. Xenobiotica 24:603–611.
    OpenUrlPubMed
  55. ↵
    1. Tracy TS and
    2. Hall SD
    (1992) Metabolic inversion of (R)-ibuprofen. Epimerization and hydrolysis of ibuprofenyl-coenzyme A. Drug Metab Dispos 20:322–327.
    OpenUrlAbstract
  56. ↵
    1. Uno S,
    2. Kawase A,
    3. Tsuji A,
    4. Tanino T, and
    5. Iwaki M
    (2007) Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis. Drug Metab Pharmacokinet 22:313–321.
    OpenUrlPubMed
  57. ↵
    1. Uno S,
    2. Uraki M,
    3. Komura H,
    4. Ikuta H,
    5. Kawase A, and
    6. Iwaki M
    (2008) Impaired intrinsic chiral inversion activity of ibuprofen in rats with adjuvant-induced arthritis. Xenobiotica 38:1410–1421.
    OpenUrlPubMed
  58. ↵
    1. Uno S,
    2. Uraki M,
    3. Ito A,
    4. Shinozaki Y,
    5. Yamada A,
    6. Kawase A, and
    7. Iwaki M
    (2009) Changes in mRNA expression of ABC and SLC transporters in liver and intestines of the adjuvant-induced arthritis rat. Biopharm Drug Dispos 30:49–54.
    OpenUrlPubMed
  59. ↵
    1. Walker KA,
    2. Barber HE, and
    3. Hawksworth GM
    (1986) Mechanism responsible for altered propranolol disposition in adjuvant-induced arthritis in the rat. Drug Metab Dispos 14:482–486.
    OpenUrlAbstract
  60. ↵
    1. Williams RC Jr.
    (1992) Rheumatoid factors: historical perspective, origins and possible role in disease. J Rheumatol Suppl 32:42–45.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 45 (3)
Drug Metabolism and Disposition
Vol. 45, Issue 3
1 Mar 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stereoselective Pharmacokinetics and Chiral Inversion of Ibuprofen in Adjuvant-induced Arthritic Rats
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Stereoselective Pharmacokinetics of Ibuprofen in Inflammation

Hiroyuki Ikuta, Atsushi Kawase and Masahiro Iwaki
Drug Metabolism and Disposition March 1, 2017, 45 (3) 316-324; DOI: https://doi.org/10.1124/dmd.116.073239

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Stereoselective Pharmacokinetics of Ibuprofen in Inflammation

Hiroyuki Ikuta, Atsushi Kawase and Masahiro Iwaki
Drug Metabolism and Disposition March 1, 2017, 45 (3) 316-324; DOI: https://doi.org/10.1124/dmd.116.073239
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TMDD Affects PK of IL-10 Fc-Fusion Proteins
  • In Vitro Models to Study P-gp-Mediated Intestinal DDIs
  • Covalent Inactivation of CYP3A by Futibatinib
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics